Axsome Therapeutics Reports Q1 2025 Earnings with Strong Revenue Growth
Axsome Therapeutics (AXSM) reported Q1 2025 earnings with total product revenue of $121.5 million, a 62% increase year-over-year, driven by its products Auvelity and Sunosi. The company also highlighted strong growth in new patient starts and prescriptions for Auvelity, though Sunosi saw a slight sequential decline in prescriptions.
Tickers: $AXSM
Topics: Financial Performance Pharmaceuticals Product Sales Revenue Growth